Literature DB >> 23744570

Leishmaniasis: clinical syndromes and treatment.

B S McGwire1, A R Satoskar.   

Abstract

Leishmaniasis is a global term for cutaneous and visceral anthroponotic and zoonotic diseases caused by the vector-borne parasites of the genus Leishmania. These diseases afflict at least 2 million people each year with more than 350 million at risk in 98 countries worldwide. These are diseases mostly of the impoverished making prevention, diagnosis and treatment difficult. Therapy of leishmaniasis ranges from local treatment of cutaneous lesions to systemic, often toxic, therapy for disseminated cutaneous, mucocutaneous and deadly visceral disease. This review is a summary of the clinical syndromes caused by Leishmania and treatment regimens currently used for various forms of leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23744570      PMCID: PMC3869292          DOI: 10.1093/qjmed/hct116

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  50 in total

1.  Treatment of Bolivian mucosal leishmaniasis with miltefosine.

Authors:  J Soto; J Toledo; L Valda; M Balderrama; I Rea; R Parra; J Ardiles; P Soto; A Gomez; F Molleda; C Fuentelsaz; G Anders; H Sindermann; J Engel; J Berman
Journal:  Clin Infect Dis       Date:  2006-12-27       Impact factor: 9.079

2.  Efficacy of extended (six weeks) treatment with miltefosine for mucosal leishmaniasis in Bolivia.

Authors:  Jaime Soto; Jaime Rea; Margarita Valderrama; Julia Toledo; Luis Valda; Jaime Ardiles; Jonathan Berman
Journal:  Am J Trop Med Hyg       Date:  2009-09       Impact factor: 2.345

Review 3.  Cutaneous and mucocutaneous leishmaniasis.

Authors:  Consuelo V David; Noah Craft
Journal:  Dermatol Ther       Date:  2009 Nov-Dec       Impact factor: 2.851

4.  Efficacy of thermotherapy to treat cutaneous leishmaniasis caused by Leishmania tropica in Kabul, Afghanistan: a randomized, controlled trial.

Authors:  R Reithinger; M Mohsen; M Wahid; M Bismullah; R J Quinnell; C R Davies; J Kolaczinski; J R David
Journal:  Clin Infect Dis       Date:  2005-03-16       Impact factor: 9.079

5.  Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India.

Authors:  R A Bumb; N Prasad; K Khandelwal; N Aara; R D Mehta; B C Ghiya; P Salotra; L Wei; S Peters; A R Satoskar
Journal:  Br J Dermatol       Date:  2013-05       Impact factor: 9.302

6.  Old world Leishmania infantum cutaneous leishmaniasis unresponsive to liposomal amphotericin B treated with topical imiquimod.

Authors:  Juan A Hervás; Ana Martín-Santiago; Daniel Hervás; Estrella Rojo; Ana Mena; Vicente Rocamora; Joaquín Dueñas
Journal:  Pediatr Infect Dis J       Date:  2012-01       Impact factor: 2.129

7.  Immunological correlates of cure in the first American cutaneous leishmaniasis patient treated by immunotherapy in Argentina. A case report.

Authors:  María Fernanda García Bustos; Alejandra Beatriz Barrio; Cecilia Maria Parodi Ramoneda; Federico Ramos; María Celia Mora; Jacinto Convit; Miguel Angel Basombrío
Journal:  Invest Clin       Date:  2011-12       Impact factor: 0.683

8.  Therapy of Venezuelan patients with severe mucocutaneous or early lesions of diffuse cutaneous leishmaniasis with a vaccine containing pasteurized Leishmania promastigotes and bacillus Calmette-Guerin: preliminary report.

Authors:  Jacinto Convit; Marian Ulrich; María Argelia Polegre; Angela Avila; Noris Rodríguez; Maria Ilina Mazzedo; Belkis Blanco
Journal:  Mem Inst Oswaldo Cruz       Date:  2004-03-31       Impact factor: 2.743

Review 9.  Post-kala-azar dermal leishmaniasis as an immune reconstitution inflammatory syndrome in a patient with acquired immune deficiency syndrome.

Authors:  S Antinori; E Longhi; G Bestetti; R Piolini; V Acquaviva; A Foschi; S Trovati; C Parravicini; M Corbellino; L Meroni
Journal:  Br J Dermatol       Date:  2007-09-13       Impact factor: 9.302

10.  Molecular basis of antimony treatment in leishmaniasis.

Authors:  Paola Baiocco; Gianni Colotti; Stefano Franceschini; Andrea Ilari
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

View more
  84 in total

1.  Visceral Leishmaniasis in a patient with rheumatoid arthritis undergoing treatment with methotrexate: Case report and review of the literature.

Authors:  Kyriakos Trigkidis; Eleni Geladari; Evangelos Kokkinakis; Natalia Vallianou
Journal:  Eur J Rheumatol       Date:  2017-04-11

2.  Efficacy and Safety of Liposomal Amphotericin B for the Treatment of Mucosal Leishmaniasis from the New World: A Retrospective Study.

Authors:  Mirella A Cunha; Aline C Q Leão; Rita de Cassia Soler; José Angelo L Lindoso
Journal:  Am J Trop Med Hyg       Date:  2015-10-19       Impact factor: 2.345

3.  Metabolomics as a tool to evaluate the toxicity of formulations containing amphotericin B, an antileishmanial drug.

Authors:  Délia C M Santos; Marta L Lima; Juliano S Toledo; Paula A Fernandes; Marta M G Aguiar; Ángeles López-Gonzálvez; Lucas A M Ferreira; Ana Paula Fernandes; Coral Barbas
Journal:  Toxicol Res (Camb)       Date:  2016-10-12       Impact factor: 3.524

4.  MicroRNA 155 Contributes to Host Immunity against Leishmania donovani but Is Not Essential for Resolution of Infection.

Authors:  Sanjay Varikuti; Gayathri Natarajan; Greta Volpedo; Bhawana Singh; Omar Hamza; Gretchen V Messick; Mireia Guerau-de-Arellano; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

5.  In vitro anti-leishmanial activity of Satureja hortensis and Artemisia dracunculus extracts on Leishmania major promastigotes.

Authors:  Farzaneh Mirzaei; Ali Fattahi Bafghi; Mohammad Ali Mohaghegh; Hossein Zarei Jaliani; Roghiyeh Faridnia; Hamed Kalani
Journal:  J Parasit Dis       Date:  2016-01-14

6.  Assessing Knowledge, Attitudes, and Preventive Practices Related to Kala-A: A Study of Rural Madhepura, Bihar, India.

Authors:  Dipti Govil; Harihar Sahoo; Sarang P Pedgaonkar; Kailash Chandra Das; Hemkhothang Lhungdim
Journal:  Am J Trop Med Hyg       Date:  2017-12-21       Impact factor: 2.345

7.  Comparative genomics of Tunisian Leishmania major isolates causing human cutaneous leishmaniasis with contrasting clinical severity.

Authors:  Amel Ghouila; Fatma Z Guerfali; Chiraz Atri; Aymen Bali; Hanene Attia; Rabiaa M Sghaier; Ghada Mkannez; Nicholas J Dickens; Dhafer Laouini
Journal:  Infect Genet Evol       Date:  2016-11-04       Impact factor: 3.342

8.  Design of protease-resistant pexiganan enhances antileishmanial activity.

Authors:  Manjusha M Kulkarni; Anna Karafova; Wojciech Kamysz; Bradford S McGwire
Journal:  Parasitol Res       Date:  2014-05       Impact factor: 2.289

9.  Novel Heteroaryl Selenocyanates and Diselenides as Potent Antileishmanial Agents.

Authors:  Ylenia Baquedano; Verónica Alcolea; Miguel Ángel Toro; Killian Jesús Gutiérrez; Paul Nguewa; María Font; Esther Moreno; Socorro Espuelas; Antonio Jiménez-Ruiz; Juan Antonio Palop; Daniel Plano; Carmen Sanmartín
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Transgenic T cell-specific expression of CXCR3 enhances splenic and hepatic T cell accumulation but does not affect the outcome of visceral leishmaniasis.

Authors:  Sanjay Varikuti; Gayathri Natarajan; Steve Oghumu; Rachel H Sperling; Ellen Moretti; James Stock; Tracey L Papenfuss; Abhay R Satoskar
Journal:  Cell Immunol       Date:  2016-09-06       Impact factor: 4.868

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.